Stehman F B, Blessing J A, Homesley H D, Currie J L, Yordan E L
Invest New Drugs. 1984;2(3):331-3. doi: 10.1007/BF00175387.
In an on-going Phase II evaluation, dianhydrogalactitol (NSC 132313) was administered intravenously to 28 patients with advanced or recurrent non-squamous cell carcinoma of the cervix. The initial dosage was 60 mg/m2/wk with escalation to 75 mg/m2/wk if there were no adverse effects. Twenty-seven patients were evaluable for toxicity and response. There was one complete response and one partial response. Adverse effects were not infrequent but tolerable.
在一项正在进行的II期评估中,对28例晚期或复发性宫颈非鳞状细胞癌患者静脉注射了双去水半乳糖醇(NSC 132313)。初始剂量为60mg/m²/周,如果没有不良反应则增至75mg/m²/周。27例患者可评估毒性和反应。有1例完全缓解和1例部分缓解。不良反应并不罕见,但可以耐受。